Recombinant protein vaccines, which are obtained by conventional genetic engineering, are based on the proteins of target pathogens that can activate our immune systems. Unlike other types of vaccines ...

The engineering and production of antibodies are vital in drug discovery, offering effective and precise therapeutics and diagnostic/prognostic materials for numerous diseases. Antibodies are proteins ...

Tsukuba, Japan—Recombinant protein production for pharmaceuticals and other applications often involves infecting plants with bacteria carrying specific genes to accumulate desired proteins in plants.

Antibodies are the number one immune cells that fight against infection and diseases. However, beyond their natural usage, biochemistry has devised several ways in which these antibodies can be ...

All G's human lactoferrin will be bio-equivalent to the native form with greater than 95% purity. As the company's first recombinant human milk protein, it marks a step toward improving early life ...

The COVID-19 pandemic and geopolitical conflict in Eastern Europe have done irreparable damage to the underpinnings of the clinical diagnostic industry. These events significantly impacted the supply ...

All G is gearing up to launch its first product—recombinant bovine lactoferrin—in Q1 2026, says CEO Jan Pacas.

First anthrax vaccine developed using recombinant DNA technology- Annual production capacity of up to 10 million doses at GC Biopharma's facility YONGIN, South Korea, Dec. 8, 2025 /PRNewswire/ -- GC ...

The history of antibody engineering and production in drug discovery can be traced back to the 1970s and 1980s [1] when scientists first began to explore the potential of using antibodies as ...

Antibody engineering and production are essential tools in drug discovery, providing powerful and specific therapeutics and diagnostic/prognostic materials for various diseases. Antibodies are ...